PDXO 384-well plate assay is highly reliable, robust and suitable for HTS.

a) Signal to noise ratio across 129 PDXO lines as defined by the luminescence ratio of vehicle/positive control with median value shown; b) Z-prime for intraplate analysis of 138 PDXO models in a 384-well format with a median value above industry standards; c) Interplate analysis (52 pairs of IC₅₀ data sets across 2 passages shown on each axis for 6 models) with r value of 0.97 and r² value of 0.94 (Pearson’s correlation). d) SOC (cisplatin, paclitaxel, gemcitabine and 5-FU) response across multiple models from different cancer types with representative IC₅₀ values plotted in waterfall format, where IC₅₀<1μM was classed as sensitive; e) Pancreatic PDXOs (PA2847, PA5389 and PA1252) dose-response (% of vehicle control ± SEM) to gemcitabine (♦), MK1775 (▲) and MK8776 (●); f) 3D response surface plot of synergy score via Bliss mathematical model for gemcitabine + MK1775 (left) or gemcitabine + MK1775 MK8776 (right) in the PA2847 PDXO model with red representing high scores and green representing low scores.